Login to Your Account



NewCo News

Start-up Ra Pharma Emerges from Stealth, Targeting HAE

By Marie Powers
Staff Writer

Wednesday, August 8, 2012

Four years after its launch and two years after the company quietly secured a $27 million Series A round, Ra Pharmaceuticals Inc. revealed hereditary angioedema (HAE) as the initial target for its cyclomimetics – peptide-like molecules that incorporate non-natural amino acids.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription